Scarica l'app Stockscreener
0.5988
3.48%
-0.0216
Dopo l'orario di chiusura:
.59
-0.0088
-1.47%
Precedente Chiudi:
$0.6204
Aprire:
$0.61
Volume 24 ore:
2.40M
Relative Volume:
1.35
Capitalizzazione di mercato:
$47.96M
Reddito:
$101.21M
Utile/perdita netta:
$-569.00K
Rapporto P/E:
-29.94
EPS:
-0.02
Flusso di cassa netto:
$-56.88M
1 W Prestazione:
-2.67%
1M Prestazione:
-24.63%
6M Prestazione:
-52.10%
1 anno Prestazione:
-72.15%
Intervallo 1D:
$0.57
$0.624
Intervallo di 1 settimana:
$0.57
$0.777
Portata 52W:
$0.57
$5.85
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Nome
Cytomx Therapeutics Inc
Settore
Industria
Telefono
650.515.3185
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Confronta CTMX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
0.5988 | 47.96M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-04-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-18 | Aggiornamento | Barclays | Underweight → Overweight |
| 2021-11-15 | Iniziato | BTIG Research | Buy |
| 2021-05-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Iniziato | JP Morgan | Overweight |
| 2021-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-06-01 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-24 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-11-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-05-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-11-26 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-15 | Iniziato | Goldman | Neutral |
| 2018-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2018-06-01 | Iniziato | SunTrust | Buy |
| 2018-01-05 | Iniziato | Citigroup | Buy |
| 2017-09-08 | Iniziato | Wedbush | Outperform |
| 2017-03-27 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-01-03 | Downgrade | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
CytomX at Barclays Healthcare: Probody Platform Progress - Investing.com India
CytomX Therapeutics’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News
CytomX Therapeutics (NASDAQ:CTMX) Upgraded by StockNews.com to “Buy” Rating - Defense World
What Are You Thinking About Investing In CytomX Therapeutics Inc (NASDAQ: CTMX) Stock? - Stocks Register
CytomX Therapeutics’ (CTMX) Outperform Rating Reiterated at Wedbush - Defense World
Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue - Investing.com India
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of “Moderate Buy” by Brokerages - Armenian Reporter
CytomX Therapeutics’ (CTMX) “Neutral” Rating Reiterated at HC Wainwright - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2024 Earnings Call Transcript - Insider Monkey
CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability - TipRanks
CytomX Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now - Insider Monkey
Deal Watch: Amgen, CytomX Pull Back On Part Of T-Cell Engager Collaboration - Citeline News & Insights
Cautious Outlook for CytomX Therapeutics Amid Pipeline Challenges and Strategic Setbacks - TipRanks
CytomX stock plunges to 52-week low, touches $0.6 By Investing.com - Investing.com Canada
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Insights - GuruFocus.com
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
CytomX Therapeutics Inc earnings beat by $0.43, revenue topped estimates - Investing.com South Africa
CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
CytomX Therapeutics Reports Strong 2024 Financial Results - TipRanks
CytomX To Report Colorectal Cancer Trial Data Of CX-2051 In 1H, 2025 - Nasdaq
CytomX Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: CytomX Therapeutics Q4 2024 reports strong revenue By Investing.com - Investing.com UK
CYTOMX THERAPEUTICS Earnings Results: $CTMX Reports Quarterly Earnings - Nasdaq
CytomX Therapeutics Inc Reports Q4 EPS of $0.38 and Revenue of $138.1 Million, Surpassing Estimates - GuruFocus.com
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates - Yahoo Finance
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update - The Manila Times
CytomX Therapeutics Advances CX-2051 and CX-801 Programs, Reports Strengthened Financial Position - Nasdaq
CytomX stock plunges to 52-week low, touches $0.6 - Investing.com India
Daily Progress: CytomX Therapeutics Inc (CTMX) Drop -5.76, Closing at 0.62 - The Dwinnex
10 Cheap Growth Stocks to Buy Now - Insider Monkey
CytomX Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect? - MSN
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference - The Manila Times
Can CytomX's Conference Presentation Reveal New Strategic Directions for Its Masked Biologics Platform? - StockTitan
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q4 202 - GuruFocus.com
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q4 2024 Result - Yahoo Finance
CytomX Therapeutics (CTMX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday - Defense World
CytomX Therapeutics (NASDAQ:CTMX) Stock Crosses Below Fifty Day Moving AverageShould You Sell? - MarketBeat
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - The Manila Times
When Will CytomX Release Q4 2024 Results? Key Date for Biotech Investors - StockTitan
CytomX faces Nasdaq delisting over share price woes - Investing.com India
CytomX faces Nasdaq delisting over share price woes By Investing.com - Investing.com South Africa
CytomX stock hits 52-week low at $0.74 amid market challenges - Investing.com Nigeria
CytomX stock hits 52-week low at $0.74 amid market challenges By Investing.com - Investing.com South Africa
Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):